Propranolol, a non-selective β-adrenergic receptor antagonist, is commonly used for hypertension myocardial infarction, anxiety and tremor. It has been found to be safe and effective in treating large infantile hemangioma. Here, we aimed to investigate the effects of propranolol on the proliferation of HT-29 human colorectal adenocarcinoma cells in vitro. HT-29 cells were seeded at a density of 2.5 x 104 cells per ml into 96-well microplates and incubated for 24h to allow sufficient cell adhesion, then treated with various concentrations of propranolol (1-250 µM) for 24, 48, and 72 hours. 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazoliumbromide (MTT) assay was performed to ascertain cell proliferation. Data were analyzed using SPSS software and IC50 values were calculated by probit analysis (non-linear regression). MTT assay showed that the cell proliferation was significantly decreased as the concentration of propranolol increases. After treatment with 100 µM of propranolol for 24, 48 and 72 h, cell proliferation decreased by 10.78%, 34.43%, and 57.37%, respectively (p<0.05). The IC50 of 24, 48, and 72 hrs of propranolol treatment for HT-29 cells was 192, 86.2, and 63.6 μM respectively, which indicates that propranolol could effectively inhibit proliferation of HT 29 cells. In conclusion, our study demonstrates that treatment of HT-29 cells with propranolol resulted in a strong cell proliferation inhibition in a dose- and time-dependent manner. The results suggest a potential role for propranolol as an anticancer agent and also provide a rationale for continuing anti-cancer research for propranolol in the treatment of colorectal cancer. ORCID NO: 0000-0003-2833-3133
Anahtar Kelimeler: Anti-cancer, Beta-blockers, Colorectal cancer, HT-29 cells, Propranolol
|
